Showing 1,201 - 1,220 results of 1,840 for search '"clinical researcher"', query time: 0.07s Refine Results
  1. 1201
  2. 1202
  3. 1203
  4. 1204
  5. 1205
  6. 1206
  7. 1207
  8. 1208
  9. 1209
  10. 1210
  11. 1211
  12. 1212
  13. 1213
  14. 1214
  15. 1215
  16. 1216

    Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk by Green RP, Blum K, Lewandrowski KU, Gold MS, Lewandrowski AP, Thanos PK, Dennen CA, Baron D, Elman I, Sharafshah A, Modestino EJ, Badgaiyan RD

    Published 2025-01-01
    “…Louis, Missouri, USA; 8Department of Biological Sciences, Dornsife College of Letters, Arts & Sciences, University of Southern California, Los Angeles, CA, USA; 9Behavioral Neuropharmacology and Neuroimaging Laboratory, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, Clinical Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA; 10Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA; 11Department of Psychiatry, Stanford University School of Medicine, Palo Alto, CA, USA; 12Department of Psychiatry, Harvard University School of Medicine, Cambridge, MA, USA; 13Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 14Brain & Behavior Laboratory, Department of Psychology, Curry College, Milton, Massachusetts, USA; 15Department of Psychiatry, Texas Tech University Health Sciences, School of Medicine, Midland, TX, USACorrespondence: Rajendra D Badgaiyan; Kenneth Blum, Email badgaiyan@gmail.com; drd2gene@gmail.com…”
    Get full text
    Article
  17. 1217

    Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership by Tess Harris, Albert Ong, Paul J D Winyard, Richard N Sandford, Maryrose Tarpey, Hannah R Bridges, Wendy D Brown, Natasha L O’Brien, Ann C Daly, Bharat K Jindal, Gillian S Mundy, Albert J Power, John Sayer, Roslyn J Simms, Patricia D Wilson

    Published 2022-06-01
    “…Fundamental basic science and clinical research on ADPKD is underway worldwide but no one has yet considered which areas should be prioritised to maximise returns from limited future funding. …”
    Get full text
    Article
  18. 1218

    Can primary care research be conducted more efficiently using routinely reported practice-level data: a cluster randomised controlled trial conducted in England? by Jeremy Horwood, Alastair D Hay, Patricia Jane Lucas, Clare Clement, Peter S Blair, Jodi Taylor, Christie Cabral, Martin C Gulliford, Jenny Ingram, Padraig Dixon, Nick Francis, Athene Lane, Grace Young, Elizabeth Beech, Penny Seume, Scott Bevan, Sam T Creavin

    Published 2022-07-01
    “…By using aggregate level, routinely collected data for the coprimary outcomes, we removed the need to recruit individual participants.Setting Primary care.Participants Baseline data from general practitioner practices and interviews with individuals from Clinical Research Networks (CRNs) in England who helped recruit practices and Clinical Commission Groups (CCGs) who collected outcome data.Intervention The intervention included: (1) explicit elicitation of parental concerns, (2) a prognostic algorithm to identify children at low risk of hospitalisation and (3) provision of a printout for carers including safety-netting advice.Coprimary outcomes For 0–9 years old—(1) Dispensing data for amoxicillin and macrolide antibiotics and (2) hospital admission rate for RTI.Results We recruited 294 of the intended 310 practices (95%) representing 336 496 registered 0–9 years old (5% of all 0–9 years old children). …”
    Get full text
    Article
  19. 1219

    Liver Radioembolization: a New Chapter in Russian Oncology by A. D. Kaprin, S. A. Ivanov, V. V. Kucherov, A. P. Petrosyan, K. V. Mayorov, N. V. Markov, L. O. Petrov, G. A. Davydov, M. A. Sigov, N. K. Silantieva, T. P. Berezovskaya, A. Yu. Usacheva, D. B. Sanin

    Published 2019-12-01
    “…Annually, over 200 thousand patients with inoperable primary liver cancer and over 270 thousand patients with inoperable metastatic liver cancer are registered globally, for whom radioembolization is considered as the most suitable treatment method. 90Y is a pure beta emitter without its own gamma line, which is characterized by a small average particle path in the tissue of 2.5 mm (the maximum level is 11 mm), a maximum beta particle energy of 2.27 MeV (average energy of 0.937 MeV) and a half-life of 64.1 hours. Clinical research into microspheres containing 90Y has been actively conducted since 1977 all over the world. …”
    Get full text
    Article
  20. 1220